KYMR
What one share of Kymera Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients’ lives.
Kymera Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.13 |
|---|---|
| Profit | −$3.21 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.55 |
| Cash and investments | $1.50 |
| Book value | $18.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $1.73 | −$24.28 | $0.31 | $10.23 | — | −$38.56 |
| 2020 | $1.96 | −$3.15 | $0.52 | $4.56 | — | — |
| 2021 | $1.52 | −$2.09 | $0.03 | −$2.72 | — | $8.92 |
| 2022 | $0.87 | −$2.87 | $0.05 | −$2.89 | — | $8.91 |
| 2023 | $1.35 | −$2.52 | $0.59 | −$2.35 | — | $7.11 |
| 2024 | $0.63 | −$2.98 | $0.17 | −$2.76 | — | $12.88 |
| 2025 | $0.46 | −$3.69 | $0.02 | −$2.77 | — | $19.42 |